Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.

HCPLive Five at European Renal Association (ERA) Congress 2025

Panelists discuss how the complexity of diagnosing C3 glomerulopathy (C3G), the need for long-term treatment options, and the importance of addressing unmet needs, including the psychological impact on patients and families, highlights the challenges and future directions in improving care for these individuals.

Treating the Whole Patient: Addressing the Broader Unmet Needs in C3G Management

Panelists discuss how patient history, vaccination status, and risk of infection influence the decision to administer complement inhibitors, with some expressing caution in high-risk cases, particularly in pediatric populations with prior infections or low immunoglobulin levels.

Balancing Complement Inhibition and Infection Risk in C3G Treatment

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives. 

ERA 2025 Recap: 5 Studies to Know

An analysis of the VALIANT trial provides insight into the benefits of pegcetacoplan in patients with C3G and IC-MPGN. 

Pegcetacoplan Could Halt Disease Progression in C3 Glomerulopathy, IC-MPGN, with Daniel Gale, PhD, MB BChir

52-week data from the VALIANT program shed further light on the potential of pegcetacoplan in C3G and IC-MPGN.

Pegcetacoplan Sustains Proteinuria Reductions in C3G, IC-MPGN at 52 Weeks

Panelists discuss how future clinical trials for C3 glomerulopathy (C3G) and other rare kidney diseases must evolve to accommodate emerging therapies targeting the complement system, improve inclusivity across patient populations, utilize molecular and genetic data, and reassess end point criteria to overcome challenges in patient recruitment and demonstrate treatment efficacy.

The Future of Clinical Trials on C3G: Lessons From the VALIANT and APPEAR Trials

Panelists discuss how early protocol biopsies and proactive monitoring post-transplant can reveal subclinical recurrence of C3 glomerulopathy (C3G), prompting consideration of timely initiation of complement-targeting therapies to preserve graft function.

Managing Recurrent C3G for Patients Post Kidney Transplant

Brendon Neuen, MBBS, PhD, discusses 3 late breaking clinical trials being presented at ERA 2025. 

ERA 2025 Preview: Late Breakers to Watch, with Brendon Neuen, MBBS, PhD

Panelists discuss how the long-term use and potential discontinuation of new complement inhibitors in C3 glomerulopathy (C3G), remain uncertain, emphasizing the need for individualized approaches, careful monitoring, and future data to guide decisions.

The Current Uncertainty in C3G Medication Treatment Discontinuation

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.